Accord BioPharma's HERCESSI™ (trastuzumab-strf) Gains Preferred Status on Express Scripts National Commercial Formularies
PR Newswire —
HERCESSI™ becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 /PRNewswire/ -- Accord BioPharma Inc., the specialty division of Intas Pharmaceuticals, Ltd.,...